Rare diseases

The PBS subsidises imatinib for patients with rare diseases.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with imatinib under the National Health Act 1953, section 85 for patients with rare diseases.

Where the term rare diseases appears, it refers to:

  • dermatofibrosarcoma protuberans (DFSP)
  • hypereosinophilic syndrome or chronic eosinophilic leukaemia (HES/CEL)
  • platelet-derived growth factor receptor (PDGFR) B fusion gene-positive myelodysplastic or myeloproliferative disorder (MDS/MPD)
  • aggressive systemic mastocytosis (ASM) with eosinophilia.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing imatinib.

Treatment specifics

The table below is a guide to prescribing PBS subsidised imatinib for rare diseases.

Name and dose per day Daily dose Tablet strength Authority prescription Quantity Maximum repeats
Dermatofibrosarcoma protuberans (maximum 800 mg per day) 400 mg 400 mg 1 x 400 mg 30 5
100 mg 4 x 100 mg 120 5
600 mg 100 mg 6 x 100 mg 180 5
or      
400 mg 1 x 400 mg 30 5
and      
100 mg 2 x 100 mg 60 5
800 mg 400 mg 2 x 400 mg 60 5
  100 mg 8 x 100 mg 240 5
Hypereosinophilic syndrome or chronic eosinophilic leukaemia (maximum 400 mg per day) 400 mg 400 mg 1 x 400 mg 30 5
  100 mg 4 x 100 mg 120 5
PDGFR B fusion gene-positive myelodysplastic or myeloproliferative disorder (maximum 400 mg per day) 400 mg 400 mg 1 x 400 mg 30 5
  100 mg 4 x 100 mg 120 5
Aggressive systemic mastocytosis with eosinophilia (maximum 400 mg per day) 400 mg 400 mg 1 x 400 mg 30 5
  100 mg 4 x 100 mg 120 5

Applications

To apply for initial PBS subsidised imatinib to treat rare diseases call the PBS authority approvals enquiry line .

Continuing PBS subsidised imatinib to treat rare diseases is Authority Required (Streamlined). It doesn’t need authority approval from us for listed quantities and repeats.

More information

Call the PBS authority approvals enquiry line  for more information.

Page last updated: 30 August 2019